ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Net Margin % : -69,571.34% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Income for the six months ended in Dec. 2023 was HK$-228.19 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue for the six months ended in Dec. 2023 was HK$0.33 Mil. Therefore, ImmuneOnco Biopharmaceuticals (Shanghai)'s net margin for the quarter that ended in Dec. 2023 was -69,571.34%.

The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % or its related term are showing as below:

HKSE:01541' s Net Margin % Range Over the Past 10 Years
Min: -98351.9 Med: -74861.56 Max: -14466.02
Current: -98351.9

HKSE:01541's Net Margin % is ranked worse than
97.85% of 1024 companies
in the Biotechnology industry
Industry Median: -153.97 vs HKSE:01541: -98351.90

ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Net Margin %

-14,466.02

-74,861.56

-98,351.66

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	-	-49,827.91	-169,460.32	-198,777.66	-69,571.34

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin %

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-415.044	/	0.422
	=	-98,351.66 %

ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-228.194	/	0.328
	=	-69,571.34 %

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines